Radioembolization Therapy Market
Report ID: SQMIG35D2391
Report ID: SQMIG35D2391
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35D2391 |
Region:
Global |
Published Date: February, 2026
Pages:
157
|Tables:
90
|Figures:
78
Global Radioembolization Therapy Market size was valued at USD 1.3 Billion in 2024 and is poised to grow from USD 1.44 Billion in 2025 to USD 3.17 Billion by 2033, growing at a CAGR of 10.4% during the forecast period (2026-2033).
Radioembolization therapy market is driven primarily by increasing incidence of primary and metastatic liver cancers and the demand for targeted, minimally invasive locoregional treatments. This market comprises devices, microspheres, delivery catheters, and planning software used to administer radioactive microspheres such as yttrium-90 to hepatic tumors, and it matters because it offers survival and quality-of-life benefits where systemic chemotherapy underperforms. Over time the sector has evolved from early experimental uses to commercial products like SIR-Spheres and TheraSphere, supported by pivotal trials and regulatory approvals in Europe and United States. Technological refinements in dosimetry, imaging, and catheter design have broadened clinical adoption.Building on that clinical adoption, growth in the radioembolization therapy market is driven by several key factors that create opportunities for providers and manufacturers. Improved diagnostic imaging and personalized dosimetry have enabled precise targeting, which leads to better tumor control and expands use as salvage therapy for chemo-refractory colorectal liver metastases and as a bridge or downstaging approach for hepatocellular carcinoma prior to transplantation. Favorable reimbursement reforms and growing clinical evidence encourage hospital investment, causing device iteration and competition that lower costs. Meanwhile expansion into Asia Pacific and combination trials with immunotherapies produce new indications, translating into larger addressable markets.
How is AI improving treatment precision in the radioembolization therapy market?
AI is improving precision in radioembolization by linking advanced imaging with machine learning to support personalized planning and intra procedural guidance. Key aspects include automated vessel segmentation perfusion assessment and AI based dosimetry which help clinicians predict how microspheres will distribute and tailor catheter position and dose to each tumor. The current state shows vendors embedding AI into imaging and planning workflows so teams can reduce variability between operators and refine target selection. This convergence of image guidance planning and predictive analytics is making treatments more consistent and is increasing clinical confidence in radioembolization technology.Sirtex Medical September 2025, the company received expanded CE mark approval for SIR Spheres Y 90 resin microspheres which broadens clinical use and supports adoption. AI driven planning and imaging tools complement that development by improving dose targeting and catheter placement which boosts procedural efficiency and market uptake.
Market snapshot - (2026-2033)
Global Market Size
USD 1.3 Billion
Largest Segment
Radioactive Beads
Fastest Growth
Radioactive Beads
Growth Rate
10.4% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global radioembolization therapy market is segmented by device type, indication, end user and region. Based on device type, the market is segmented into Chemoembolization Devices, Radioactive Beads and Delivery Systems. Based on indication, the market is segmented into Liver Cancer, Colorectal Cancer and Other Tumors. Based on end user, the market is segmented into Hospitals, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Radioactive Beads segment dominates because their capacity to deliver concentrated radioisotopes directly within tumor vasculature aligns with the core therapeutic rationale of radioembolization, producing targeted tumoricidal effects while sparing healthy tissue. This clinical fit has driven clinician preference, manufacturer focus, and repeatable procedural workflows, which together reinforce adoption, supplier investment, and ongoing refinement of bead properties and handling to support consistent therapeutic outcomes.
However, Delivery Systems are witnessing the strongest growth momentum as improvements in catheter technology, imaging integration, and precision targeting enhance procedural safety and access. These innovations enable more complex interventions, encourage broader clinician adoption, and create commercial opportunities for manufacturers to develop integrated platforms that expand radioembolization indications and procedural throughput.
Liver Cancer segment leads because radioembolization aligns with the organ-specific biology and vascular supply of primary hepatic tumors, positioning it as a practical locoregional therapy within multidisciplinary care pathways. That clinical alignment fosters strong referral patterns, guideline recognition, and institutional investment, which in turn motivate manufacturers and centers to optimize devices, training, and protocols to meet clinician expectations and ongoing patient demand.
On the other hand, Colorectal Cancer is emerging as the most rapidly expanding indication due to growing evidence supporting treatment of hepatic metastases and an uptick in combination approaches with systemic therapies. Expanding clinical research and evolving referral networks are driving broader use, prompting device adaptation and procedural innovation that create new opportunities for market growth and cross-disciplinary collaboration.
To get detailed segments analysis, Request a Free Sample Report
North America dominates due to a confluence of advanced clinical infrastructure, concentrated centers of excellence and a mature medical device and radiopharmaceutical industry that together accelerate adoption. Strong multidisciplinary care models link hepatology, oncology and interventional radiology, enabling streamlined patient pathways and higher procedural throughput. Robust clinical research activity and collaborative networks with industry refine clinical protocols and support rapid dissemination of best practices. Regulatory clarity and established reimbursement frameworks reduce barriers to uptake, while extensive practitioner training and advanced imaging capabilities ensure consistent procedural quality. Supply chain maturity and proactive payer engagement further enable broader geographic access within major healthcare systems, sustaining market leadership and ongoing innovation.
Radioembolization Therapy Market in United States is characterized by widespread availability of interventional oncology services concentrated in academic medical centers and specialized hospitals. Clinician familiarity, intensive training programs and strong industry presence support rapid technology adoption and iterative clinical refinement. Integrated care pathways and favorable reimbursement landscapes in major health systems facilitate referrals and procedural standardization. The combination of research engagement, advanced imaging resources and commercial investment ensures continued maturation of service delivery and patient access across diverse care settings.
Radioembolization Therapy Market in Canada reflects centralized healthcare decision making with provincial coordination that channels complex cases to tertiary centers. Specialized hospitals and provincial cancer agencies collaborate on technology assessment and practitioner education, supporting careful adoption and regional scale up. Public payer frameworks emphasize evidence generation and cost effectiveness, shaping procurement and referral patterns. Emphasis on equitable access and integration into multidisciplinary liver cancer programs strengthens procedural availability and aligns clinical practice with national standards across provinces.
The rapid expansion in Europe is driven by growing clinical evidence demonstrating therapeutic value, expansion of specialist interventional oncology centers and an active medtech manufacturing base that supplies devices and radiopharmaceuticals. Pan regional collaboration among clinical societies and increasing guideline recognition support standardized pathways and broader clinician acceptance. Health technology assessment and evolving reimbursement models are enabling wider adoption in both public and private settings. Cross border referral activity and centers of excellence promote knowledge transfer, while investment in practitioner training and advanced imaging infrastructure improves procedural capability. Regulatory harmonization and commercial partnerships further facilitate market entry and scale up, accelerating the integration of radioembolization into standard oncologic care across multiple healthcare systems.
Radioembolization Therapy Market in Germany benefits from a dense network of specialized hospitals and a strong interventional radiology community that prioritizes minimally invasive oncology treatments. Hospital based centers of excellence, robust clinician training programs and close industry collaboration drive clinical adoption and procedural refinement. Reimbursement mechanisms and institutional investments in hybrid operating rooms and imaging support sustained procedural volumes. A strong domestic medtech industry and active participation in clinical research underpin ongoing innovation and service expansion within the healthcare landscape.
Radioembolization Therapy Market in United Kingdom is emerging through expanding specialist centers and structured evaluation frameworks within national health services that emphasize clinical value and equitable access. Growing investment in interventional oncology capacity and focused training initiatives are improving practitioner expertise and referral pathways. Collaborative networks between academic hospitals and regional providers support dissemination of best practices. Health technology assessment and pilot programs facilitate adoption in targeted centers, promoting steady integration of radioembolization into multidisciplinary cancer care protocols.
Radioembolization Therapy Market in France is experiencing rapid momentum driven by proactive clinical research, regional centers of excellence and supportive evaluation by health authorities. Hospital networks with strong interventional radiology expertise are scaling procedural capability and integrating radioembolization into liver cancer treatment pathways. Collaboration between academic institutions and industry accelerates adoption through local studies and training initiatives. Emphasis on evidence generation and coordinated referral processes enhances access and positions the market for continued clinical integration across major treatment centers.
Asia Pacific is strengthening its position through targeted investment in cancer care infrastructure, expanding networks of tertiary hospitals and growing local expertise in interventional oncology. Regional manufacturers and international partnerships are increasing availability of devices and radiopharmaceuticals, supported by focused clinician training and technology transfer initiatives. Regulatory agencies in several markets are creating clearer pathways for device and therapy approval, while payers and hospitals are gradually recognizing the clinical value within multidisciplinary oncology programs. Cross border collaboration, participation in clinical studies and rising emphasis on advanced imaging and hybrid procedural suites are enhancing procedural capability and patient access across diverse healthcare systems in the region.
Radioembolization Therapy Market in Japan reflects a sophisticated healthcare environment with strong imaging infrastructure and concentrated centers that lead clinical adoption. Academic hospitals and research institutions contribute to evidence generation and practitioner training, fostering integration into multidisciplinary liver cancer care. Regulatory pathways and hospital procurement processes support careful introduction of new technologies, while collaboration between industry and clinical centers promotes post market evaluation and procedural optimization. The result is a measured but steady expansion of service capability within specialized institutions.
Radioembolization Therapy Market in South Korea is advancing through a network of high capability tertiary hospitals and a competitive private hospital sector that drive rapid clinical uptake. Strong emphasis on procedural innovation, clinician training and integrated oncology services supports incorporation of radioembolization into treatment algorithms. Active collaboration with device suppliers and participation in clinical studies enhance local expertise. Centralized referral patterns to specialized centers and investment in imaging and hybrid suites continue to strengthen service delivery and patient access across major metropolitan regions.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Prevalence Of Liver Tumors
Technological Advances In Therapies
High Procedural Costs and Logistics
Reimbursement and Policy Uncertainty
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape in radioembolization is concentrated among legacy device makers, with M&A and targeted acquisitions reshaping supply and tech. Examples include Boston Scientific’s BTG acquisition for TheraSphere and Terumo’s acquisition of Quirem for holmium SIRT, while Sirtex advanced delivery platforms like SIROS and FLEXdose. Players pursue partnerships with radiopharma CDMOs and imaging vendors to secure supply chains and dosimetry differentiation.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the global radioembolization therapy market is expanding as rising prevalence of liver tumors drives demand for targeted locoregional treatments and supports adoption of established microsphere platforms. North America remains the dominant region, led by advanced clinical infrastructure and reimbursement pathways, while the radioactive beads segment dominates clinical use due to precise intratumoral radiation delivery. Growth is further supported by improved diagnostic imaging and personalized dosimetry that enable better targeting and outcomes. Adoption is moderated by high procedural costs and complex logistics that limit uptake in smaller centers and concentrate services in tertiary hospitals. Overall, clinical evidence, device refinement and integrative care models underpin steady market momentum.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 1.3 Billion |
| Market size value in 2033 | USD 3.17 Billion |
| Growth Rate | 10.4% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Radioembolization Therapy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Radioembolization Therapy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Radioembolization Therapy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Radioembolization Therapy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
